# Dose Escalation of Clofarabine in Combination With Cytarabine and Idarubicin as Induction Therapy in High Risk AML

> **NCT01534702** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Hannover Medical School** · enrollment: 60 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** clofarabine, cytarabine, idarubicin

## Key facts

- **NCT ID:** NCT01534702
- **Lead sponsor:** Hannover Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-01
- **Primary completion:** 2013-04
- **Final completion:** 2015-09
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2012-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01534702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01534702, "Dose Escalation of Clofarabine in Combination With Cytarabine and Idarubicin as Induction Therapy in High Risk AML". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01534702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*